Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new ...

MarketBeat Week in Review – 7/15 - 7/19 IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress ...

Temporary sheriff Ulysses Richardson (Bob Odenkirk) is assigned to Minnesotan small-town Normal — where things turn out to be anything but. In a familiar Western-vibed plot that’s essentially Assault ...

Odenkirk plays a washed-up sheriff whose arrival in an eerily wholesome Minnesota town sets off a chain of violence, corruption and savage Ben Wheatley shootouts Bob Odenkirk continues his new career ...

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion Japanese yen ($610 million) hit linked to its precautionary antibody-drug ...

Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and ...

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but ...

ADC can be combined with immunotherapy, such as immune checkpoint inhibitors, to increase tumor cell killing (right panel). (A) Immune checkpoint blockade leads to T-cell activation, (B) whereas ADC ...

Deb Hipp is a freelance health and medical writer and editor who lives in Kansas City, Missouri. She is a former investigative reporter with more than 25 years of experience as a journalist and writer ...